search
Back to results

Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations

Primary Purpose

Schizophrenia, Auditory Hallucination, Treatment-resistant Schizophrenia

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
stg-rt-fMRI-Neurofeeback
sham-rt-fMRI-Neurofeedback
Sponsored by
Boston VA Research Institute, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Schizophrenia focused on measuring Auditory-Hallucination, Connectivity, brain-activity, default-mode-network, superior temporal gyrus, Neurofeedback, MRI

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • patients diagnosed with SZ or schizoaffective disorder using DSM-5 criteria
  • auditory hallucinations not responsive to pharmacology as determined by chart review and a clinical interview of SCID.

Exclusion Criteria:

  • neurologic illness
  • major head trauma
  • electroconvulsive therapy
  • alcohol or drug dependence
  • alcohol or drug abuse within the past five years
  • verbal IQ below 70

Sites / Locations

  • Boston VA Healthcare System, BrocktonRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

stg-rt-fMRI

sham-rt-fMRI

Arm Description

will receive feedback from the STG

will receive feedback from the motor cortex

Outcomes

Primary Outcome Measures

percent change in the STG BOLD signal, post- relative to pre-NFB
does real-time fMRI neurofidback reduce BOLD activity in STG, post NFB

Secondary Outcome Measures

reduction in scores on Psychotic Symptoms Rating Scale, post- relative to pre, NFB
does real-time fMRI neurofidback reduce auditory hallucinations, post NFB
percent change in the MPFC-PCC connectivity measure, post- relative to pre-NFB.
Does real time NFB reduce connectivity in MPFC-PCC, post NFB

Full Information

First Posted
March 8, 2022
Last Updated
September 20, 2022
Sponsor
Boston VA Research Institute, Inc.
Collaborators
Mclean Hospital, Northeastern University, Cambridge Health Alliance
search

1. Study Identification

Unique Protocol Identification Number
NCT05299749
Brief Title
Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations
Official Title
Real-time fMRI Neurofeedback as a Tool to Mitigate Auditory Hallucinations in Patients With Schizophrenia - R33 Phase
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
March 1, 2022 (Actual)
Primary Completion Date
June 30, 2024 (Anticipated)
Study Completion Date
June 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Boston VA Research Institute, Inc.
Collaborators
Mclean Hospital, Northeastern University, Cambridge Health Alliance

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Neurofeedback intervention aimed to regulate the superior temporal gyrus (STG) activation and default mode network (DMN) connectivity as well as to reduce the auditory hallucinations (AH) schizophrenia patients with medication resistant AH.
Detailed Description
Here, the investigators propose that neurofeedback aimed to regulate the superior temporal gyrus (STG) activation will not only lead to activation changes in the STG, but also to changes in the default mode network (DMN), as well as to reductions in AH, and that the brain and clinical changes will be correlated. The theoretical framework for the current proposal is an AH model that assumes that AH result from abnormalities in a network of regions including STG, and medial prefrontal cortex (MPFC) and posterior cingulate cortex (PCC), the two latter regions are core medial hubs of DMN that are related to self-referential processing. This model is supported by several theoretical papers and experimental evidence well as preliminary data by the investigators (PD). In both R61 and R33 the investigators will study SZ patients with medication resistant AH in the rt-fMRI intervention arm and in the sham-rt-fMRI arm. In both arms, the task and the rt-fMRI session structure will be identical. The SZ-intervention group will receive feedback from the STG while SZ-sham group will receive feedback from the motor cortex. In addition, 2 functional fMRI tasks will examine the effect of rt-fMRI neurofeedback and of sham-rt-fMRI on brain response. This R33 phase will consist of an SZ-intervention group (random n=52) that will receive 5 sessions of rt-fMRI feedback targeting STG, while SZ-sham group (random n=52) will receive 5 sham-rt-fMRI sessions. Based on our R61 phase data, the investigators predict that rt-fMRI feedback aimed at STG will reduce AH which will be, in turn, associated with reductions in the STG activation and in the DMN connectivity (i.e., brain changes achieved in R61 and replicated in R33) in SZ- intervention group only. Five sessions of rt-fMRI feedback will address the question of dose response at brain and clinical levels. The impact of rt-fMRI neurofeedback and of sham-rt-fMRI on AH (primary outcome), and on delusions, negative symptoms and working memory (WM) (exploratory outcome) will be assessed with clinical and neuropsychological measures. In an exploratory aim, based on the existing literature, the investigators predict the improvement in delusions, negative symptoms and in WM score, only post-rt-fMRI neurofeedback targeting the STG and not post-sham-rt-fMRI.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia, Auditory Hallucination, Treatment-resistant Schizophrenia
Keywords
Auditory-Hallucination, Connectivity, brain-activity, default-mode-network, superior temporal gyrus, Neurofeedback, MRI

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
104 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
stg-rt-fMRI
Arm Type
Experimental
Arm Description
will receive feedback from the STG
Arm Title
sham-rt-fMRI
Arm Type
Sham Comparator
Arm Description
will receive feedback from the motor cortex
Intervention Type
Other
Intervention Name(s)
stg-rt-fMRI-Neurofeeback
Intervention Description
the patients will receive real-time feedback from the brain activity of the superior temporal gyrus
Intervention Type
Other
Intervention Name(s)
sham-rt-fMRI-Neurofeedback
Intervention Description
the patients will receive real-time feedback from the brain activity of the somato-motor cortex
Primary Outcome Measure Information:
Title
percent change in the STG BOLD signal, post- relative to pre-NFB
Description
does real-time fMRI neurofidback reduce BOLD activity in STG, post NFB
Time Frame
0-4 weeks post intervention
Secondary Outcome Measure Information:
Title
reduction in scores on Psychotic Symptoms Rating Scale, post- relative to pre, NFB
Description
does real-time fMRI neurofidback reduce auditory hallucinations, post NFB
Time Frame
0-4 weeks post intervention
Title
percent change in the MPFC-PCC connectivity measure, post- relative to pre-NFB.
Description
Does real time NFB reduce connectivity in MPFC-PCC, post NFB
Time Frame
0-4 weeks post intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: patients diagnosed with SZ or schizoaffective disorder using DSM-5 criteria auditory hallucinations not responsive to pharmacology as determined by chart review and a clinical interview of SCID. Exclusion Criteria: neurologic illness major head trauma electroconvulsive therapy alcohol or drug dependence alcohol or drug abuse within the past five years verbal IQ below 70
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Margaret Niznikiewicz, PhD
Phone
617-855-2570
Email
lstone@mclean.harvard.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Lena Stone
Email
lstone@mclean.harvard.edu
Facility Information:
Facility Name
Boston VA Healthcare System, Brockton
City
Brockton
State/Province
Massachusetts
ZIP/Postal Code
02301
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lena Stone
Phone
617-855-2570
Email
LSTONE@MCLEAN.HARVARD.EDU

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
The Clinical, Cognitive and Imaging data will be made publicly available

Learn more about this trial

Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations

We'll reach out to this number within 24 hrs